7 Results for "

HBV genome

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "HBV genome" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-109168
CAS No.: 1638266-40-6
Purity:  99.24%
Synonyms: JNJ-6379; JNJ-56136379
Target:  

HBV DNA/RNA Synthesis

Research Areas:  

Infection

Bersacapavir (JNJ-6379) is an HBV capsid assembly modulator. Bersacapavir exerts a dual mechanism of action against both early and late stages of HBV infection by forming complete genome-free empty capsids and inhibiting de novo synthesis of cccDNA. Bersacapavir inhibits HBV replication. Bersacapavir can be used in the research of hepatitis B .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-131343
CAS No.: 2305897-84-9
Purity:  99.37%
Target:  

HBV DNA/RNA Synthesis

Research Areas:  

Infection

HBV-IN-4, a phthalazinone derivative, is a potent and orally active HBV DNA replication inhibitor with an IC50 of 14 nM. HBV-IN-4 induces the formation of genome-free capsids and has potent anti-HBV potencies .
loading...
    loading...
Cat. No.: HY-145638A
CAS No.: 2538784-49-3
Purity:  95.90%
Synonyms: RO7445482 sodium
Target:  

HBV

Research Areas:  

Infection

Xalnesiran (RO7445482) sodium is a small interfering RNA molecule that targets a conserved region of the
hepatitis B virus (HBV) genome . Xalnesiran sodium can be used for the research of chronic hepatitis B infection .
loading...
    loading...
Cat. No.: HY-145638
CAS No.: 2538784-48-2
Synonyms: RO7445482
Target:  

HBV

Research Areas:  

Infection

Xalnesiran (RO7445482) is a small interfering RNA molecule that targets a conserved region of the
hepatitis B virus (HBV) genome. Xalnesiran can be used for the research of chronic hepatitis B infection .
loading...
    loading...
Cat. No.: HY-173121
Target:  

HBV

Research Areas:  

Infection

KR019 is a potent HBV capsid assembly modulator, exhibits potent antiviral activity in HBV-replicating cells. KR019 binds to the hydrophobic pocket at the core protein dimer-dimer interface, misdirecting capsid assembly into genome-free capsids and thereby inhibiting viral replication .
loading...
    loading...
Cat. No.: HY-109168R
CAS No.: 1638266-40-6
Synonyms: JNJ-6379 (Standard); JNJ-56136379 (Standard)
Research Areas:  

Infection

Bersacapavir (Standard) is the analytical standard of Bersacapavir (HY-109168). This product is intended for research and analytical applications. Bersacapavir is an HBV capsid assembly modulator. Bersacapavir exerts a dual mechanism of action against both early and late stages of HBV infection by forming complete genome-free empty capsids and inhibiting de novo synthesis of cccDNA. Bersacapavir inhibits HBV replication. Bersacapavir can be used in the research of hepatitis B .
loading...
    loading...
Cat. No.: HY-L027
1,237 compounds

Viruses are much simpler organisms than bacteria, and they are made from protein substances and nucleic acid. Despite the fact that the exact mechanism of infection is extremely specific to each type of virus, the general scheme of infection can be represented in the following manner: A virus is absorbed at the surface of a host cell and then permeates through the membrane, where it releases nucleic acid from its protein protection. Then the viral nucleic acid begins to replicate, and transcription of the viral genome takes place either in the cytoplasm, or in the nucleus of the host cell. As a result of these events, a large amount of viral nucleic acid and protein are made to make new generations of virions. Therefore, one mechanism of action of antiviral drugs is to interfere with the ability of a virus to get into a target cell. A second mechanism of action is to target the processes that synthesize virus components after a virus invades a cell, such as nucleotide or nucleoside analogs.

MCE designs a unique collection of 1,237 anti-virus compounds that target several viruses, including SARS-CoV, HBV, HCV, HIV, HSV and Influenza Virus. It’s an effective tool for anti-virus drug discovery.